Bloomberg -- David Brennan couldn’t sit still. During a meal of beef and potatoes at AstraZeneca Plc’s drug research center near Stockholm in October, Brennan, the company’s chief executive officer, grilled six drug-development managers over a concern raised by a laboratory scientist. That morning, the newly recruited researcher told Brennan during a town hall-style meeting that he didn’t have the freedom he would have in academia to pursue unusual ideas. Brennan wanted to know why.
